HealthEquity’s Long-Term Growth Intact Despite Short-Term Margin Pressures, Analyst Says

HealthEquity reported 19% revenue growth but missed Q4 EPS estimates. Analysts see earnings improving as cybersecurity costs ease and HSA growth continues.

Latest Ratings for HQY

DateFirmActionFromTo Feb 2022Deutsche BankMaintainsBuy Dec 2021JP MorganMaintainsOverweight Dec 2021Deutsche BankMaintainsBuy

View More Analyst Ratings for HQY

View the Latest Analyst Ratings

read more